Form 4: AYTU CFO Ryan Selhorn Boosts Stake with Equity Grants
Insider Transaction Report
AYTU BioPharma's Chief Financial Officer, Ryan J. Selhorn, increased his beneficial ownership by 33,743 shares through restricted stock grants.
Summary
- Ryan J. Selhorn, Chief Financial Officer of AYTU BioPharma, Inc., acquired 33,743 shares of common stock on October 3, 2025.
- This includes 16,243 fully vested restricted shares received in lieu of cash as an annual bonus.
- An additional 17,500 restricted shares were granted, with 1/3 vesting on October 3, 2026, and the remaining shares vesting in 8 equal quarterly installments beginning January 3, 2027.
- Following these transactions, Selhorn's direct beneficial ownership in AYTU BioPharma totals 49,743 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as a key executive is increasing their stake in the company through compensation, aligning their interests with shareholders. This is a routine transaction and not indicative of major news.
Positives
- Chief Financial Officer Ryan J. Selhorn increased his direct beneficial ownership in AYTU BioPharma by 33,743 shares, aligning his interests with shareholders.
- The grants include 16,243 fully vested restricted shares as an annual bonus, indicating performance-based compensation.
- An additional 17,500 restricted shares were granted, demonstrating ongoing equity incentives for key management.
Future Outlook
A portion of the restricted stock grant, specifically 17,500 shares, will vest over time, with 1/3 vesting on October 3, 2026, and the remaining shares vesting in 8 equal quarterly installments beginning January 3, 2027.
Industry Context
This filing is a standard disclosure of insider equity transactions and does not provide broader industry context or trends. It reflects a company's compensation strategy for its executives.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Ryan Selhorn granted a Limited Power of Attorney to several individuals, including Jake Siciliano, Ryan Selhorn, Luke Schafer, Fei Gao, and Joshua Disbrow, to execute and file Forms 3, 4, and 5 on his behalf with the SEC. | 2025-09-17 | Streamlines the process for insider transaction reporting, ensuring timely compliance with Section 16(a) of the Exchange Act. |
Stakeholder Impact
- Shareholders: Increased insider ownership may be viewed positively as it aligns management's financial interests with those of the shareholders.
- Employees: Reflects the company's executive compensation structure, which may influence broader compensation policies.
Next Steps
- Vesting of 1/3 of the 17,500 restricted shares on October 3, 2026.
- Commencement of quarterly vesting for the remaining restricted shares starting January 3, 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-09-17 | Execution date of the Limited Power of Attorney for SEC Section 16(a) filings. |
| 2025-10-03 | Date of common stock acquisition transactions for Ryan J. Selhorn. |
| 2025-10-07 | Signature date of the Form 4 filing by Ryan J. Selhorn. |
| 2026-10-03 | Vesting date for 1/3 of the 17,500 restricted stock grant. |
| 2027-01-03 | Start date for remaining restricted stock vesting in 8 equal quarterly installments. |
Keywords
AYTU BioPharma, AYTU, Ryan J. Selhorn, Chief Financial Officer, CFO, Insider Transaction, Form 4, Restricted Stock, Equity Grant, Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.